Skip to main content
Theralase Technologies Inc. logo

Theralase Technologies Inc. — Investor Relations & Filings

Ticker · TLT ISIN · CA88337V1004 LEI · 529900NI3Y8GLE2IBF28 TSXV Manufacturing
Open in API
Filings indexed 698 across all filing types
Latest filing 2021-06-08 Regulatory Filings
Country CA Canada
Listing TSXV TLT

About Theralase Technologies Inc.

https://theralase.com/

Theralase Technologies Inc. designs, develops, manufactures, and markets patented laser technology platforms for both bio-stimulative and bio-destructive medical applications. The company operates two core divisions. The first is Cool Laser Therapy (CLT), which utilizes proprietary super-pulsed laser systems for therapeutic purposes, focusing on pain management, inflammation reduction, tissue repair, and the effective elimination of chronic knee pain. The second is Anti-Cancer Therapy (ACT), which employs patented light-activated Photo Dynamic Compounds (PDCs) combined with laser technology for destructive applications, specifically targeting the safe and effective destruction of cancer, bacteria, and viruses.

Recent filings

Filing Released Lang Actions
Form of proxy - English.pdf
Regulatory Filings
2021-06-08 English
Other.pdf
Regulatory Filings Classification · 100% confidence The document is an Officer's Certificate pursuant to a specific regulatory instrument (National Instrument 54-101) related to communication with beneficial owners of securities. It certifies compliance with proxy material distribution requirements for an upcoming annual general meeting. The document is short (1080 characters) and primarily a certification letter without substantive financial data or detailed report content. According to the Certification Rule, such officer certifications should be classified as Regulatory Filings (RNS), not as the report or meeting materials themselves.
2021-06-08 English
Notice of meeting - English.pdf
AGM Information Classification · 95% confidence The document is a Notice of Annual General and Special Meeting of Shareholders for Theralase Technologies Inc. It includes details about the meeting date, agenda items such as election of directors, appointment of auditors, consideration of audited financial statements, and other shareholder business. The document is a formal notice inviting shareholders to attend and vote, but it does not contain the actual meeting materials, financial statements, or results. The length is 2498 characters, which is relatively short and consistent with a meeting notice rather than a full report or transcript. Therefore, this document fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting, specifically the notice of the meeting itself.
2021-06-08 English
52-109FV1 - Certification of annual filings - CEO (E).pdf
Regulatory Filings Classification · 100% confidence The document is a certification by the CEO of Theralase Technologies Inc regarding the annual filings for the financial year ended December 31, 2020. It explicitly states it is a 'Certification of annual filings - venture issuer basic certificate' under Form 52-109FV1. The content focuses on the CEO's review and attestation of the annual filings, including the AIF, annual financial statements, and annual MD&A, but does not contain the actual financial data or the full annual report itself. The document is primarily an officer certification letter, which according to the Certification Rule, should be classified as a Regulatory Filing (RNS) rather than the Annual Report (10-K) or other report types. The document length is short (3145 characters), and it does not contain substantive financial statements or analysis, only the certification. Therefore, the correct classification is Regulatory Filings (RNS).
2021-06-04 English
52-109FV1 - Certification of annual filings - CFO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a certification statement by the Chief Financial Officer regarding the annual filings of Theralase Technologies Inc for the financial year ended December 31, 2020. It references the annual financial statements, annual MD&A, and AIF, but does not contain the actual financial data or detailed report content itself. The document is a formal attestation of the accuracy and fair presentation of the annual filings, consistent with a certification under National Instrument 52-109 for venture issuers. It is short (3141 characters) and primarily a certification letter rather than the full annual report or financial statements. According to the Certification Rule, such officer certifications should be classified as Regulatory Filings (RNS), not as the report they reference (e.g., 10-K or Annual Report).
2021-06-04 English
Annual information form - English.pdf
Annual Report Classification · 95% confidence The document is titled 'Annual Information Form Year-ended December 31, 2020' and dated June 3, 2021. It contains detailed sections such as Corporate Structure, Business Description, Risk Factors, Dividends, Capital Structure, Directors and Officers, Legal Proceedings, and other comprehensive corporate information. The length is substantial (15,000 characters), indicating it is a full report rather than a brief announcement. The Annual Information Form (AIF) is a detailed disclosure document commonly filed in Canadian jurisdictions, similar in purpose to an annual report but distinct from a 10-K. Given the detailed business overview, risk factors, and corporate governance information, this filing aligns best with the Annual Report category (10-K equivalent). It is not a simple announcement or certification, nor is it a quarterly or interim report. Therefore, the appropriate classification is Annual Report (10-K). FY 2020
2021-06-04 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.